| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| Cost of Revenue | $31K | -90.9% | — |
| R&D Expense | $2.8M | +40.7% | — |
| SG&A Expense | $2.9M | +21.3% | — |
| Operating Income | -$5.7M | -21.3% | — |
| Net Income | -$10.1M | -156.3% | -22.9% |
| EPS (Basic) | -$0.66 | -153.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.7M | -43.0% | -83.5% |
| Accounts Receivable | $35K | — | -61.1% |
| Inventory | $1.5M | -15.9% | -62.6% |
| Current Assets | $8.1M | -33.4% | -76.8% |
| Total Assets | $31.5M | -12.1% | -70.6% |
| Current Liabilities | $9.7M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.9M | — | — |
| Capital Expenditures | $865K | — | — |
| Investing Cash Flow | -$865K | — | — |
| Financing Cash Flow | $15.6M | — | — |
| Free Cash Flow | -$15.7M | — | — |
| +92.1% |
| EPS (Diluted) | -$0.66 | -88.6% | — |
| +98.6% |
| +22.5% |
| Long-term Debt | $21.2M | +25.1% | +54.1% |
| Total Liabilities | $32.9M | +20.8% | +7.3% |
| Stockholders' Equity | -$1.3M | -115.1% | -101.7% |